Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases
Version 2 2023-11-01, 17:06
Version 1 2023-09-12, 08:42
media
posted on 2023-11-01, 17:06 authored by Adis journalson behalf of, Maria Fasshauer, Michael Borte, Michaela Bitzenhofer, Christine Pausch, David Pittrow, Michelle Park, André Gladiator, Peter JandusThe above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-reviewed publication” opposite).
